Product
BNT163
1 clinical trial
1 indication
Indication
Herpes Simplex Type 2Clinical trial
Phase I, Randomized, Observer-blinded, Placebo-controlled, 2-part, Dose Escalation and Expanded Safety Evaluation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Prophylactic Vaccine for the Prevention of Genital Lesions Caused by Herpes Simplex Virus (HSV)-2 and Potentially HSV-1Status: Recruiting, Estimated PCD: 2025-12-01